Cell-Specific Neuropharmacology.

Neuronal communication involves a multitude of neurotransmitters and an outstanding diversity of receptors and ion channels. Linking the activity of cell surface receptors and ion channels in defined neural circuits to brain states and behaviors has been a key challenge in neuroscience, since cell targeting is not possible with traditional neuropharmacology. We review here recent technologies that enable the effect of drugs to be restricted to specific cell types, thereby allowing acute manipulation of the brain's own proteins with circuit specificity. We highlight the importance of developing cell-specific neuropharmacology strategies for decoding the nervous system with molecular and circuit precision, and for developing future therapeutics with reduced side effects.

[1]  William Wisden,et al.  From synapse to behavior: rapid modulation of defined neuronal types with engineered GABAA receptors , 2007, Nature Neuroscience.

[2]  Richard C Saunders,et al.  Chemogenetic disconnection of monkey orbitofrontal and rhinal cortex reversibly disrupts reward value , 2015, Nature Neuroscience.

[3]  R. Kramer,et al.  Understanding and improving photo‐control of ion channels in nociceptors with azobenzene photo‐switches , 2018, British journal of pharmacology.

[4]  Dirk Trauner,et al.  Restoring Visual Function to Blind Mice with a Photoswitch that Exploits Electrophysiological Remodeling of Retinal Ganglion Cells , 2014, Neuron.

[5]  B. Roth,et al.  Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand , 2007, Proceedings of the National Academy of Sciences.

[6]  Dirk Trauner,et al.  Restoration of patterned vision with an engineered photoactivatable G protein-coupled receptor , 2017, Nature Communications.

[7]  Xi Chen,et al.  Selective chemical labeling of proteins. , 2016, Organic & biomolecular chemistry.

[8]  B. Roth.  DREADDs for Neuroscientists , 2016, Neuron.

[9]  Amy Hu,et al.  Selective esterase–ester pair for targeting small molecules with cellular specificity , 2012, Proceedings of the National Academy of Sciences.

[10]  E. Isacoff,et al.  Light-activated ion channels for remote control of neuronal firing , 2004, Nature Neuroscience.

[11]  Karl Deisseroth,et al.  Excitatory transmission at thalamo–striatal synapses mediates susceptibility to social stress , 2015, Nature Neuroscience.

[12]  Erwin Sigel,et al.  Subtle Changes in Residue 77 of the γ Subunit of α1β2γ2 GABAA Receptors Drastically Alter the Affinity for Ligands of the Benzodiazepine Binding Site* , 1997, The Journal of Biological Chemistry.

[13]  M. Nitabach,et al.  Membrane-tethered ligands: tools for cell-autonomous pharmacological manipulation of biological circuits. , 2013, Physiology.

[14]  Dirk Trauner,et al.  Dual optical control and mechanistic insights into photoswitchable group II and III metabotropic glutamate receptors , 2017, Proceedings of the National Academy of Sciences.

[15]  Russell B. Fletcher,et al.  How Azobenzene Photoswitches Restore Visual Responses to the Blind Retina , 2016, Neuron.

[16]  Hyunah Choo,et al.  The First Structure–Activity Relationship Studies for Designer Receptors Exclusively Activated by Designer Drugs , 2015, ACS chemical neuroscience.

[17]  Reid H. J. Olsen,et al.  DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs in Vitro and in Vivo , 2018, ACS pharmacology & translational science.

[18]  O. Sadovski,et al.  Near-Infrared Photoswitching of Azobenzenes under Physiological Conditions. , 2017, Journal of the American Chemical Society.

[19]  Liwang Liu,et al.  Habenula cholinergic neurons regulate anxiety during nicotine withdrawal via nicotinic acetylcholine receptors , 2016, Neuropharmacology.

[20]  C. M. Davenport,et al.  Engineering a Light-Regulated GABAA Receptor for Optical Control of Neural Inhibition , 2014, ACS chemical biology.

[21]  Fei Chen,et al.  A fully genetically-encoded protein architecture for optical control of peptide ligand concentration , 2014, Nature Communications.

[22]  S. Sternson,et al.  Chemogenetic Tools for Causal Cellular and Neuronal Biology. , 2018, Physiological reviews.

[23]  Karl Deisseroth,et al.  Integration of optogenetics with complementary methodologies in systems neuroscience , 2017, Nature Reviews Neuroscience.

[24]  D. O'Leary,et al.  In Vivo Expression of a Light-Activatable Potassium Channel Using Unnatural Amino Acids , 2013, Neuron.

[25]  M. Nitabach,et al.  Tethering toxins and peptide ligands for modulation of neuronal function , 2012, Current Opinion in Neurobiology.

[26]  Dirk Trauner,et al.  Tuning photochromic ion channel blockers. , 2011, ACS chemical neuroscience.

[27]  I. Ibañez-Tallon,et al.  Silencing neurotransmission with membrane-tethered toxins , 2010, Nature Methods.

[28]  Dirk Trauner,et al.  Rapid optical control of nociception with an ion channel photoswitch , 2012, Nature Methods.

[29]  Dirk Trauner,et al.  LiGluR restores visual responses in rodent models of inherited blindness. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  SNAP-Tagged Nanobodies Enable Reversible Optical Control of a G Protein-Coupled Receptor via a Remotely Tethered Photoswitchable Ligand. , 2018, ACS chemical biology.

[31]  A. Schier,et al.  Optical Control of Metabotropic Glutamate Receptors , 2013, Nature Neuroscience.

[32]  Dirk Trauner,et al.  Orthogonal Optical Control of a G Protein-Coupled Receptor with a SNAP-Tethered Photochromic Ligand , 2015, ACS central science.

[33]  M. Michaelides,et al.  Ultrapotent chemogenetics for research and potential clinical applications , 2019, Science.

[34]  R. Dubner,et al.  Central Terminal Sensitization of TRPV1 by Descending Serotonergic Facilitation Modulates Chronic Pain , 2014, Neuron.

[35]  M. Nitabach,et al.  Membrane-tethered ligands are effective probes for exploring class B1 G protein-coupled receptor function , 2009, Proceedings of the National Academy of Sciences.

[36]  Timothy W. Dunn,et al.  Optogenetic Photochemical Control of Designer K Ϩ Channels in Mammalian Neurons , 2022 .

[37]  S. Sternson,et al.  Cell type-specific pharmacology of NMDA receptors using masked MK801 , 2015, eLife.

[38]  Xi-Ping Huang,et al.  A New DREADD Facilitates the Multiplexed Chemogenetic Interrogation of Behavior , 2015, Neuron.

[39]  Dirk Trauner,et al.  Photochromic blockers of voltage-gated potassium channels. , 2009, Angewandte Chemie.

[40]  Dirk Trauner,et al.  In Vivo Photopharmacology. , 2018, Chemical reviews.

[41]  Liwang Liu,et al.  Functional Upregulation of α4* Nicotinic Acetylcholine Receptors in VTA GABAergic Neurons Increases Sensitivity to Nicotine Reward , 2015, The Journal of Neuroscience.

[42]  Henry A. Lester,et al.  Neuronal P2X transmitter-gated cation channels change their ion selectivity in seconds , 1999, Nature Neuroscience.

[43]  Youngnam Kang,et al.  Selectively targeting pain in the trigeminal system , 2010, PAIN.

[44]  Brenda C. Shields,et al.  Deconstructing behavioral neuropharmacology with cellular specificity , 2017, Science.

[45]  R. Kramer,et al.  Manipulating midbrain dopamine neurons and reward-related behaviors with light-controllable nicotinic acetylcholine receptors , 2018, eLife.

[46]  Z. Gartner,et al.  Cell-Specific Chemical Delivery Using a Selective Nitroreductase-Nitroaryl Pair. , 2018, ACS chemical biology.

[47]  A. Taly,et al.  Optical control of an ion channel gate , 2013, Proceedings of the National Academy of Sciences.

[48]  M. Caterina,et al.  TRPV1 shows dynamic ionic selectivity during agonist stimulation , 2008, Nature Neuroscience.

[49]  Raag D. Airan,et al.  Temporally precise in vivo control of intracellular signalling , 2009, Nature.

[50]  C. M. Davenport,et al.  A Comprehensive Optogenetic Pharmacology Toolkit for In Vivo Control of GABAA Receptors and Synaptic Inhibition , 2015, Neuron.

[51]  D. Kullmann,et al.  Olanzapine: A potent agonist at the hM4D(Gi) DREADD amenable to clinical translation of chemogenetics , 2019, Science Advances.

[52]  E. Isacoff,et al.  Allosteric control of an ionotropic glutamate receptor with an optical switch , 2006, Nature chemical biology.

[53]  M. Bruchas,et al.  Optogenetic approaches for dissecting neuromodulation and GPCR signaling in neural circuits. , 2017, Current opinion in pharmacology.

[54]  E. Isacoff,et al.  Optical Control of Dopamine Receptors Using a Photoswitchable Tethered Inverse Agonist. , 2017, Journal of the American Chemical Society.

[55]  D. Trauner,et al.  Specificity and Speed: Tethered Photopharmacology. , 2017, Biochemistry.

[56]  H. Lester,et al.  Insights into the Neurobiology of the Nicotinic Cholinergic System and Nicotine Addiction from Mice Expressing Nicotinic Receptors Harboring Gain-of-Function Mutations , 2012, Pharmacological Reviews.

[57]  L. Looger,et al.  Chemical and Genetic Engineering of Selective Ion Channel–Ligand Interactions , 2011, Science.

[58]  G. Ellis‐Davies,et al.  Optical control of neuronal ion channels and receptors , 2019, Nature Reviews Neuroscience.

[59]  Dirk Trauner,et al.  Optochemical control of genetically engineered neuronal nicotinic acetylcholine receptors. , 2012, Nature chemistry.

[60]  E. Isacoff,et al.  A Toolkit for Orthogonal and in vivo Optical Manipulation of Ionotropic Glutamate Receptors , 2016, Front. Mol. Neurosci..

[61]  Clifford J. Woolf,et al.  Inhibition of nociceptors by TRPV1-mediated entry of impermeant sodium channel blockers , 2007, Nature.

[62]  Ehud Y. Isacoff,et al.  Optical Control of Endogenous Proteins with a Photoswitchable Conditional Subunit Reveals a Role for TREK1 in GABAB Signaling , 2012, Neuron.

[63]  Herwig Baier,et al.  Remote Control of Neuronal Activity with a Light-Gated Glutamate Receptor , 2007, Neuron.

[64]  E. Isacoff,et al.  A family of photoswitchable NMDA receptors , 2016, eLife.

[65]  Thomas Wichmann,et al.  Metabolism and Distribution of Clozapine-N-oxide: Implications for Nonhuman Primate Chemogenetics. , 2017, ACS chemical neuroscience.

[66]  D. Trauner,et al.  Conditional and Reversible Activation of Class A and B G Protein-Coupled Receptors Using Tethered Pharmacology , 2018, ACS central science.

[67]  Brandon K. Harvey,et al.  Chemogenetics revealed: DREADD occupancy and activation via converted clozapine , 2017, Science.

[68]  Peter G. Schultz,et al.  A chemical switch for inhibitor-sensitive alleles of any protein kinase , 2000, Nature.

[69]  M. Gold,et al.  Gi-DREADD Expression in Peripheral Nerves Produces Ligand-Dependent Analgesia, as well as Ligand-Independent Functional Changes in Sensory Neurons , 2016, The Journal of Neuroscience.

[70]  Jason W. Chin,et al.  Selective, rapid and optically switchable regulation of protein function in live mammalian cells. , 2015, Nature chemistry.

[71]  Han-Woong Lee,et al.  Expanding the genetic code of Mus musculus , 2017, Nature Communications.

[72]  E. Smith,et al.  An in vivo tethered toxin approach for the cell-autonomous inactivation of voltage-gated sodium channel currents in nociceptors , 2010, The Journal of physiology.

[73]  I. Hamachi,et al.  Chemogenetic Approach Using Ni(II) Complex–Agonist Conjugates Allows Selective Activation of Class A G-Protein-Coupled Receptors , 2018, ACS central science.

[74]  David P. Roberson,et al.  Targeting of sodium channel blockers into nociceptors to produce long‐duration analgesia: a systematic study and review , 2011, British journal of pharmacology.

[75]  Paul Brehm,et al.  Tethering Naturally Occurring Peptide Toxins for Cell-Autonomous Modulation of Ion Channels and Receptors In Vivo , 2004, Neuron.